Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2017

View Archived Issues

Lakewood-Amedex advancing second bisphosphocin candidate

Sentien Biotechnologies closes series A financing to fund development of SBI-101

FDA grants orphan drug designation to valproic acid for DLBCL

ProMetic Life Sciences completes plasminogen BLA filing

ConverGene enters CRADA with NINDS

Promising preclinical data for novel first-in-class pan-FGFR antibody, MM-161

Finch Therapeutics, Takeda to jointly develop FIN-524 for IBD

Pivotal ZEUS trial of Zolyd in cUTI meets primary endpoint

Allergan reports data from proof-of-concept phase II trial of Botox in major depressive disorder

Ligand and Marinus enter new agreement for Captisol-enabled ganaxolone

Charles River Laboratories and Nimbus Therapeutics enter strategic partnership

FUJIFILM presents novel irreversible and potent FLT3 inhibitor for AML treatment

Battelle and Nanotherapeutics form alliance on medical countermeasures

Enumeral Biomedical enters MoU with ICAV to pursue infectious disease collaboration

Takeda enrolls more than 20,000 children and adolescents in phase III dengue vaccine trial

R-IMPP, a new small molecule anti-secretagogue of PCSK9 with a new mechanism of action

Galapagos doses first patient in EQUATOR study of filgotinib

Corbus Pharmaceuticals to begin phase III study of anabasum in systemic sclerosis

First-in-human results for GSK-2881078 in the treatment of muscle wasting

Marina Biotech provides corporate update

Suven Life Sciences presents muscarinic acetylcholine M1 receptor PAMs

Calitor Sciences patents JAK, FLT3 and ARK kinase inhibitors

Merck KGaA divulges IRAK inhibitors

Ohio State University and collaborator identify estrogen receptor beta agonists

Metacrine discovers farnesoid X-activated receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...